Hyperfine (HYPR) Revenue Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Revenue Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.15 Bn | 176.85 Bn | 6.27 Bn | 7.78% |
| 2 | Stryker | 128.85 Bn | 125.98 Bn | 3.81 Bn | 2.63% |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 68.66 Bn | 67.21 Bn | 3.61 Bn | 11.58% |
| 5 | Edwards Lifesciences | 48.24 Bn | 44.57 Bn | 1.29 Bn | 16.70% |
| 6 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | 15.05% |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn | 7.41% |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.18 Bn | 2.07 Bn | 6.08% |
| 10 | Hyperfine | 94.23 Mn | 52.95 Mn | 1.98 Mn | 82.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.64% |
| Dec 31, 2025 | 128.05% |
| Sep 30, 2025 | -5.65% |
| Jun 30, 2025 | -25.75% |
| Mar 31, 2025 | -35.14% |
| Dec 31, 2024 | -13.59% |
| Sep 30, 2024 | 56.35% |
| Jun 30, 2024 | 7.39% |
| Mar 31, 2024 | 25.05% |
| Dec 31, 2023 | 88.62% |
| Sep 30, 2023 | -0.77% |
| Jun 30, 2023 | 120.55% |
| Mar 31, 2023 | 74.62% |
| Dec 31, 2022 | 226.61% |
| Sep 30, 2022 | 532.88% |
| Jun 30, 2022 | 328.21% |
| Mar 31, 2022 | 355.89% |